{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:19:04Z","timestamp":1789730344813,"version":"4.0.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004242","name":"Princess Nourah bint Abdulrahman University","doi-asserted-by":"publisher","award":["PNURSP2026R95"],"award-info":[{"award-number":["PNURSP2026R95"]}],"id":[{"id":"10.13039\/501100004242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109918","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:04:10Z","timestamp":1777129450000},"page":"109918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Quinoxaline-based scaffolds as dual VEGFR-2\/EGFR kinase inhibitors and apoptotic inducers: Design, synthesis, anticancer evaluation, and in silico study"],"prefix":"10.1016","volume":"177","author":[{"given":"Alaa","family":"Elwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiha A.","family":"El-Sebaey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan A.","family":"AL-Ghulikah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda R.","family":"Mabrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abo bakr","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ayman","family":"El-Zahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah E.","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona S.","family":"El-Zoghbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioorg.2026.109918_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21608\/ajps.2021.187700","article-title":"Design, molecular modeling and synthesis of new immunomodulatory agents for biological studies","volume":"64","author":"El-Zahabi","year":"2021","journal-title":"Al-Azhar Journal of Pharmaceutical Sciences"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109918_bb0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.25259\/ijmr_1729_23","article-title":"Global burden of cancer pattern in 2020 & prediction to 2040 among older adults","volume":"160","author":"Kalita","year":"2024","journal-title":"Indian J. Med. Res."},{"issue":"10229","key":"10.1016\/j.bioorg.2026.109918_bb0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.rpor.2020.04.004","article-title":"Interplay between inflammation and cancer","volume":"25","author":"Piotrowski","year":"2020","journal-title":"Reports of Practical Oncology and Radiotherapy"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","article-title":"Polytherapy and targeted cancer drug resistance","volume":"5","author":"Chatterjee","year":"2019","journal-title":"Trends in cancer"},{"key":"10.1016\/j.bioorg.2026.109918_bb0030","doi-asserted-by":"crossref","first-page":"118187","DOI":"10.1016\/j.ejmech.2025.118187","article-title":"Design, synthesis, anticancer evaluation, biological screening, and computational study of novel 6, 7-dimethoxyquinazoline derivatives as VEGFR-2 inhibitors and apoptotic inducers","volume":"301","author":"Aref","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109918_bb0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.21608\/ajps.2023.332170","article-title":"Vegfer-2 inhibitors and quinazoline-based anticancer agents","volume":"68","author":"Sakr","year":"2023","journal-title":"Al-Azhar Journal of Pharmaceutical Sciences"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109918_bb0040","first-page":"35","article-title":"Epidermal growth factor as a biomarker for early detection of hepatocellular carcinoma","volume":"3","author":"El-Araby","year":"2022","journal-title":"Al-Azhar International Medical Journal"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/13543784.16.3.367","article-title":"Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours","volume":"16","author":"Scott","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.109918_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140595","article-title":"New vatalanib analogs: design, synthesis, in silico study and biological evaluation for anticancer activity","volume":"1322","author":"Abdallah","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109918_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108784","article-title":"Design, synthesis and biological evaluation of spirocyclopropyl oxindole-piperazine\/morpholine-based carboxamides as potential anticancer agents","volume":"163","author":"Dastari","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14756366.2021.2017911","article-title":"Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors","volume":"37","author":"Abdallah","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21608\/ajps.2024.360355","article-title":"An insight on medicinal attributes of phthalazine scaffold, with a focus on their anticancer properties as vegfr-2 inhibitors","volume":"69","author":"Dahab","year":"2024","journal-title":"Al-Azhar Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.bioorg.2026.109918_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117966","article-title":"A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors","volume":"115","author":"Kashyap","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109918_bb0080","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.3390\/molecules27134079","article-title":"Design, synthesis, in silico and in vitro studies of new immunomodulatory anticancer nicotinamide derivatives targeting VEGFR-2","volume":"27","author":"Yousef","year":"2022","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109918_bb0085","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-10-0232","article-title":"The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo","volume":"16","author":"Paesler","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.bioorg.2026.109918_bb0090","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1016\/j.bmc.2011.06.022","article-title":"Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors","volume":"19","author":"Li","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109918_bb0095","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.2147\/OTT.S97644","article-title":"New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?","author":"Van Der Steen","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bioorg.2026.109918_bb0100","doi-asserted-by":"crossref","first-page":"1027890","DOI":"10.3389\/fphar.2022.1027890","article-title":"Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies","volume":"13","author":"Opo","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2516075","article-title":"Design, synthesis, and antiproliferative activity of new 5-ethylsulfonyl-indazole-3-carbohydrazides as dual EGFR\/VEGFR-2 kinases inhibitors","volume":"40","author":"Al-Wahaibi","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109918_bb0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"36","key":"10.1016\/j.bioorg.2026.109918_bb0115","doi-asserted-by":"crossref","first-page":"29593","DOI":"10.1039\/D5RA03829D","article-title":"Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study","volume":"15","author":"Mabrouk","year":"2025","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0120","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/14756366.2022.2103552","article-title":"Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation","volume":"37","author":"Taghour","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0125","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1080\/14756366.2022.2081844","article-title":"Design, synthesis, molecular modeling and biological evaluation of novel benzoxazole-benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers","volume":"37","author":"Eissa","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109918_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202303095","article-title":"Novel thiazolidine-2, 4-Dione derivatives as potential VEGFR-2 inhibitors: synthesis, biological testing, and in silico studies","volume":"9","author":"Eissa","year":"2024","journal-title":"ChemistrySelect"},{"issue":"40","key":"10.1016\/j.bioorg.2026.109918_bb0135","doi-asserted-by":"crossref","first-page":"27801","DOI":"10.1039\/D3RA05689A","article-title":"Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2, 4-dione derivatives as potential antitumor VEGFR-2 inhibitors","volume":"13","author":"Elkady","year":"2023","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0140","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1080\/14756366.2022.2110868","article-title":"Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies","volume":"37","author":"Yousef","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109918_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137753","article-title":"Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors","volume":"1305","author":"Yousef","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109918_bb0150","first-page":"1","article-title":"New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis, in vitro, and in silico studies","author":"Yousef","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"29","key":"10.1016\/j.bioorg.2026.109918_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202301401","article-title":"A review on multipurpose potential of bioactive heterocycle quinoxaline","volume":"8","author":"Chawla","year":"2023","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.109918_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135071","article-title":"Chemistry and pharmacological diversity of benzothiazepine\u2014excellent pathway to drug discovery","volume":"1280","author":"Ogunnupebi","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109918_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106342","article-title":"Research progress on the structure and biological diversities of 2-phenylindole derivatives in recent 20 years","volume":"132","author":"Wu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109918_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115172","article-title":"Application and synthesis of thiazole ring in clinically approved drugs","volume":"250","author":"Niu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109918_bb0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1039\/D0NJ02990D","article-title":"[1, 2, 4] triazolo [4, 3-a] quinoxaline and [1, 2, 4] triazolo [4, 3-a] quinoxaline-1-thiol-derived DNA intercalators: design, synthesis, molecular docking, in silico ADMET profiles and anti-proliferative evaluations","volume":"45","author":"El-Adl","year":"2021","journal-title":"New J. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109918_bb0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1871520617666170710182405","article-title":"Design and discovery of novel quinoxaline derivatives as dual DNA intercalators and topoisomerase II inhibitors","volume":"18","author":"Eissa","year":"2018","journal-title":"Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents"},{"key":"10.1016\/j.bioorg.2026.109918_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104399","article-title":"Design, synthesis, molecular docking and anti-proliferative evaluations of [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as DNA intercalators and topoisomerase II inhibitors","volume":"105","author":"El-Adl","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0190","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1080\/14756366.2022.2080205","article-title":"Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations","volume":"37","author":"Elwan","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109918_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24061175","article-title":"Design and synthesis of new quinoxaline derivatives as anticancer agents and apoptotic inducers","volume":"24","author":"El Newahie","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109918_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100359","article-title":"Targeting VEGFR-2 by new quinoxaline derivatives: design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies","volume":"355","author":"Alsaif","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.109918_bb0205","first-page":"587","article-title":"New series of VEGFR-2 inhibitors and apoptosis enhancers: design, synthesis and biological evaluation","author":"Abdallah","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109918_bb0210","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s11030-021-10303-6","article-title":"Design, synthesis and molecular docking of new [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase","volume":"26","author":"Alsaif","year":"2022","journal-title":"Mol. Divers."},{"issue":"17","key":"10.1016\/j.bioorg.2026.109918_bb0215","doi-asserted-by":"crossref","first-page":"12896","DOI":"10.1039\/D5RA00526D","article-title":"Targeting VEGFR-2 in breast cancer: synthesis and in silico and in vitro characterization of quinoxaline-based inhibitors","volume":"15","author":"Eissa","year":"2025","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0220","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1080\/14756366.2021.1945591","article-title":"Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies","volume":"36","author":"Alanazi","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0225","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/14756366.2021.1915303","article-title":"Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3\u2032, 4\u2032-c] quinoxaline derivatives as anticancer agents and apoptosis inducers","volume":"36","author":"Alsaif","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109918_bb0230","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0235","first-page":"1","article-title":"Structural verification, molecular docking and antiproliferative activity for amino acetylenic oxy quinoxalines","volume":"9","author":"MUHI-ELDEEN","year":"2019","journal-title":"Int. J. Life Sci. Pharma. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0240","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/jhet.4398","article-title":"Synthesis and biological evaluation of novel 1, 3, 4-oxadiazole derivatives as anticancer agents and potential EGFR inhibitors","volume":"59","author":"Osmaniye","year":"2022","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2026.109918_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130317","article-title":"Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors","volume":"1236","author":"Fayed","year":"2021","journal-title":"J. Mol. Struct."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109918_bb0250","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3390\/molecules26051490","article-title":"Design and synthesis of non-covalent imidazo [1, 2-a] quinoxaline-based inhibitors of EGFR and their anti-cancer assessment","volume":"26","author":"Kumar","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109918_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139839","article-title":"Design and synthesis of novel quinoxaline-piperazine linked isoxazole conjugates: anti-cancer assessment, tyrosine kinase EGFR inhibitory activity, molecular docking and DFT studies","volume":"1321","author":"Ravula","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109918_bb0260","doi-asserted-by":"crossref","first-page":"101989","DOI":"10.1016\/j.rechem.2024.101989","article-title":"An insight into the therapeutic impact of quinoxaline derivatives: recent advances in biological activities (2020\u20132024)","volume":"13","author":"Waseem","year":"2024","journal-title":"Results Chem."},{"key":"10.1016\/j.bioorg.2026.109918_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104695","article-title":"Design, synthesis and molecular modeling of new quinazolin-4 (3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation","volume":"109","author":"Abdallah","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2026.109918_bb0270","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.3390\/molecules27155047","article-title":"Modified benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, and anti-proliferative evaluation","volume":"27","author":"Elwan","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282586","article-title":"Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: computer-aided drug discovery approach","volume":"18","author":"Eissa","year":"2023","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109918_bb0280","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109918_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200048","article-title":"New quinoxalin-2 (1H)-one-derived VEGFR-2 inhibitors: design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies","volume":"355","author":"El-Adl","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.109918_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128529","article-title":"Novel benzothiazole-based dual VEGFR-2\/EGFR inhibitors targeting breast and liver cancers: synthesis, cytotoxic activity, QSAR and molecular docking studies","volume":"58","author":"Abd El-Meguid","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109918_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119531","article-title":"EGFR\/VEGFR-2 dual inhibitor and apoptotic inducer: design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives","volume":"277","author":"Mourad","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2026.109918_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106310","article-title":"Design, synthesis and molecular modeling study of certain EGFR inhibitors with a quinazolinone scaffold as anti-hepatocellular carcinoma and radio-sensitizers","volume":"131","author":"Ghorab","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109918_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2020.103498","article-title":"Cytotoxicity evaluation of ketoprofen found in pharmaceutical wastewater on HEK 293 cell growth and metabolism","volume":"80","author":"Zulkarnain","year":"2020","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109918_bb0310","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09674845.2004.11732652","article-title":"Links between apoptosis, proliferation and the cell cycle","volume":"61","author":"Alenzi","year":"2004","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.bioorg.2026.109918_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115958","article-title":"[1, 2, 4] triazolo [4, 3-c] quinazoline and bis ([1, 2, 4] triazolo)[4, 3-a: 4\u2032, 3\u2032-c] quinazoline derived DNA intercalators: design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies","volume":"30","author":"El-Adl","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0320","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1146\/annurev.biochem.68.1.383","article-title":"Mammalian caspases: structure, activation, substrates, and functions during apoptosis","volume":"68","author":"Earnshaw","year":"1999","journal-title":"Annu. Rev. Biochem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109918_bb0325","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1357-2725(99)00024-2","article-title":"Caspase-9","volume":"32","author":"Kuida","year":"2000","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5324","key":"10.1016\/j.bioorg.2026.109918_bb0330","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1126\/science.277.5324.370","article-title":"Inhibition of bax channel-forming activity by bcl-2","volume":"277","author":"Antonsson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109918_bb0335","series-title":"The Bcl-2 protein family","first-page":"50","volume":"256(1)","author":"Antonsson","year":"2000"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0340","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1080\/14756366.2021.1956488","article-title":"Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers","volume":"36","author":"Alanazi","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0345","first-page":"411","article-title":"Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of bcl-2","volume":"29","author":"Ling","year":"2009","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0350","doi-asserted-by":"crossref","first-page":"42705","DOI":"10.1038\/s41598-025-26721-7","article-title":"Biological evaluations and biomolecular interactions along with computational insights of arylidene isatin hydrazones synthesized using nanocatalyst","volume":"15","author":"Feizi-Dehnayebi","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109918_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127475","article-title":"Probing the biological activity of isatin derivatives against human lung cancer a549 cells: cytotoxicity, CT-DNA\/BSA binding, DFT\/TD-DFT, topology, ADME-tox, docking and dynamic simulations","volume":"428","author":"Feizi-Dehnayebi","year":"2025","journal-title":"J. Mol. Liq."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109918_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/cnr2.70315","article-title":"Flavonoids as promising akt1 inhibitors in cancer medicine: insights from molecular docking, dynamics, DFT calculations, and in vitro validation","volume":"8","author":"Jamshidi","year":"2025","journal-title":"Cancer Reports"},{"key":"10.1016\/j.bioorg.2026.109918_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152472","article-title":"Exploring the anticancer potential of novel benzimidazolium salts: synthesis, biological evaluation, DFT perspective, and docking simulation for inhibition of VEGFR2","volume":"780","author":"Kundu","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.109918_bb0370","first-page":"1","article-title":"A new series of pyrazoles-based compounds: synthesis, HOMO\u2013LUMO analysis, MEP, quantum reactivity, and in silico COVID-19 activity","author":"Ak\u0131n","year":"2025","journal-title":"Struct. Chem."},{"key":"10.1016\/j.bioorg.2026.109918_bb0375","article-title":"Design, synthesis, and biological evaluation of novel amidoxime or amidine analogues of some 4-anilino-6, 7-dimethoxyquinazolines with a potent EGFR inhibitory effect","volume":"158","author":"Hal\u0131c\u0131","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109918_bb0380","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14534","article-title":"Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy","volume":"103","author":"Budipramana","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2026.109918_bb0385","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0022-1759(94)90034-5","article-title":"A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia","volume":"174","author":"Van de Loosdrecht","year":"1994","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.109918_bb0390","series-title":"Rapid, ELISA-Based Measurement of Protein Tyrosine Kinase Activity Using the K-LISA\u2122 Kit","author":"Batenjany","year":"2005"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109918_bb0395","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/cancers13051027","article-title":"A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action","volume":"13","author":"Mohan","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0400","doi-asserted-by":"crossref","first-page":"28.6. 1","DOI":"10.1002\/0471142727.mb2806s111","article-title":"Assaying cell cycle status using flow cytometry","volume":"111","author":"Kim","year":"2015","journal-title":"Curr. Protoc. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109918_bb0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin v","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109918_bb0410","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.bioorg.2026.109918_bb0415","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0420","doi-asserted-by":"crossref","first-page":"641a","DOI":"10.1016\/j.bpj.2015.11.3431","article-title":"CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"110","author":"Lee","year":"2016","journal-title":"Biophys. J."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109918_bb0425","doi-asserted-by":"crossref","DOI":"10.1063\/5.0012280","article-title":"CHARMM-GUI supports the amber force fields","volume":"153","author":"Lee","year":"2020","journal-title":"J. Chem. Phys."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:37:58Z","timestamp":1783111078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":85,"alternative-id":["S0045206826004542"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109918","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinoxaline-based scaffolds as dual VEGFR-2\/EGFR kinase inhibitors and apoptotic inducers: Design, synthesis, anticancer evaluation, and in silico study","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109918"}}